Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.74 |
| ▸ | HPGD | P15428 | 2/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.70 |
| ▸ | MEN1 | O00255 | 3/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4289556 | 0.99 | KMT2A (0.72) | KDM4EALDH1A1HPGDKMT2AMEN1 | |
| SCHEMBL13609480 | 0.86 | SMN1; SMN2 (0.58) | KDM4EALDH1A1HPGDKMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL4298634 | 0.85 | SMN1; SMN2 (0.60) | KDM4EALDH1A1HPGDKMT2AMEN1 | |
| SCHEMBL2146698 | 0.83 | KMT2A (0.84) | KDM4EALDH1A1HPGDKMT2AMEN1 | |
| SCHEMBL6212951 | 0.80 | L3MBTL3 (0.66) | ALDH1A1KMT2AMEN1TSHRSMN1; SMN2 | |
| SCHEMBL27615103 | 0.80 | S1PR5 (0.57) | KDM4EALDH1A1HPGDKMT2AMEN1 | |
| SCHEMBL10947749 | 0.79 | KMT2A (0.76) | KDM4EALDH1A1HPGDKMT2AMEN1 | |
| SCHEMBL4300326 | 0.79 | L3MBTL1 (0.67) | KDM4EALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL28690097 | 0.79 | L3MBTL3 (0.64) | ALDH1A1KMT2AMEN1TSHRSMN1; SMN2 | |
| SCHEMBL13990656 | 0.79 | L3MBTL3 (0.68) | ALDH1A1KMT2AMEN1TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281097-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281097-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281097-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-2009011-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281097-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TNNC1, CPT1B, TNNI3 | KDM4E 1496/4885ALDH1A1 1550/4885HPGD 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.